The FDA issued warning letters to 30 telehealth companies for making false or misleading claims about GLP-1 compound products[1][2]. The primary violations included claims suggesting equivalence to FDA-approved drugs such as Novo Nordisk's Wegos and concealing the source of products by marketing them under a private label without clearly stating who compounded them[2][3]. This is the second wave of warning letters in six months, following a September crackdown to stop misleading direct-to-consumer advertising[2][3]. The FDA has issued thousands of letters warning pharmaceutical and telehealth companies to remove misleading ads in the past six months, more than in the entire previous decade[2][3]. The FDA has warned that compounded drugs are not FDA-approved and the agency cannot verify their safety, efficacy, or quality before they are placed on the market[3]. Companies may not claim that unregistered compounded products are generic versions or the same as FDA-approved drugs, or that they are clinically proven[6].